Cytokinetics | CYTK - Operating Expenses


Cytokinetics reported $200.58M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Arca Biopharma USD 34.43M 326K Dec/2025
Bayer EUR 9.88B 452M Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
Brainstorm Cell Therapeutics USD 2.24M 197K Dec/2025
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Capricor Therapeutics USD 29.16M 2.87M Dec/2025
Cytokinetics USD 200.58M 4.46M Mar/2026
Eisai JPY 215.74B 15.84B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Exelixis USD 359.47M 3.28M Mar/2026
Geron USD 52.07M 6.73M Mar/2026
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Ligand Pharmaceuticals USD 34.35M 5.27M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026